scholarly journals Does previous biopsy lead to cancer overdiagnosis of superficial non-ampullary duodenal epithelial tumors?

2021 ◽  
Vol 09 (01) ◽  
pp. E58-E65
Author(s):  
Shigetsugu Tsuji ◽  
Hisashi Doyama ◽  
Sho Tsuyama ◽  
Akihiro Dejima ◽  
Takashi Nakashima ◽  
...  

Abstract Background and study aims We aimed to evaluate the diagnostic performance of magnifying endoscopy with narrow-band imaging (M-NBI) in superficial non-ampullary duodenal epithelial tumors (SNADETs) regarding the absence or presence of biopsy before M-NBI diagnosis. Patients and methods Clinicopathological data were retrospectively reviewed for 99 SNADETs from 99 patients who underwent endoscopic resection. The 99 tumors were divided into the non-biopsy group (32 lesions not undergoing biopsy before M-NBI examination) and the biopsy group (67 lesions undergoing biopsy before M-NBI examination). We investigated the correlation between the M-NBI diagnosis and the histopathological diagnosis of the SNADETs in both groups. Results According to the modified revised Vienna classification, 31 tumors were classified as category 3 (C3) (low-grade adenoma) and 68 as category 4/5 (C4/5) (high-grade adenoma/cancer). The accuracy, sensitivity, and specificity of preoperative M-NBI diagnoses in the non-biopsy group vs the biopsy group were 88 % (95 % confidence interval: 71.0 – 96.5) vs 66 % (51.5 – 75.5), P = 0.02; 95 % (77.2 – 99.9) vs 89 % (76.4 – 96.4), P = 0.39; and 70 % (34.8 – 93.3) vs 14 % (3.0 – 36.3), P < 0.01, respectively. Notably, in the biopsy group, the specificity of M-NBI in SNADETs was low at only 14 % because we over-diagnosed most C3 lesions as C4/5. M-NBI findings might have been compromised by the previous biopsy procedure itself. Conclusions In the non-biopsy group, the accuracy of M-NBI in SNADETs was excellent in distinguishing C4/5 lesions from C3. The M-NBI findings in SNADETs should be evaluated while carefully considering the influence of a previous biopsy.

2017 ◽  
Vol 85 (5) ◽  
pp. AB305-AB306
Author(s):  
Shigetsugu Tsuji ◽  
Hisashi Doyama ◽  
Kunihiro Tsuji ◽  
Naohiro Yoshida ◽  
Kazuhiro Matsunaga ◽  
...  

2012 ◽  
Vol 15 (2) ◽  
pp. 170-178 ◽  
Author(s):  
Kazuhiro Miwa ◽  
Hisashi Doyama ◽  
Renma Ito ◽  
Hiroyoshi Nakanishi ◽  
Katsura Hirano ◽  
...  

Endoscopy ◽  
2017 ◽  
Vol 49 (06) ◽  
pp. 529-535 ◽  
Author(s):  
Takao Kanemitsu ◽  
Kenshi Yao ◽  
Takashi Nagahama ◽  
Kentaro Imamura ◽  
Shoko Fujiwara ◽  
...  

Abstract Background and aims Intestinal metaplasia (IM) of the stomach is associated with an increased risk of differentiated gastric cancer. While it is important to diagnose IM endoscopically, it can be difficult to observe by white-light endoscopy. In magnifying endoscopy with narrow-band imaging (M-NBI) of the stomach, a light-blue crest (LBC) is widely known to be a useful marker in the endoscopic diagnosis of IM. However, IM that exhibits only white opaque substance (WOS) without an LBC can also occur. The aim of this study was to elucidate whether the presence of WOS on M-NBI of the stomach could serve as a marker of IM in the same way that an LBC does. Methods The subjects were 40 consecutive patients who underwent M-NBI between July and December 2014. The primary endpoint in this study was to evaluate the diagnostic performance of M-NBI for histologically observed IM in WOS- and LBC-positive mucosa. Results The sensitivity and specificity of WOS for histologically diagnosed IM were 50.0 % (95 % confidence interval [CI] 40.0 % – 50.0 %) and 100.0 % (95 %CI 85.0 % – 100.0 %), respectively. Meanwhile, the sensitivity and specificity of LBC were 62.5 % (95 %CI 51.1 % – 65.9 %) and 93.8 % (95 %CI 76.7 % – 98.9 %), respectively. The sensitivity and specificity of WOS and/or LBC (WOS positive and LBC positive, WOS positive and LBC negative, or WOS negative and LBC positive) for histologically diagnosed IM were 87.5 % (95 %CI 76.9 % – 90.9 %) and 93.8 % (95 %CI 77.9 % – 98.9 %), respectively. Conclusions LBC and WOS are both useful markers for endoscopic diagnosis of IM. Combining both markers improves the sensitivity.Clinical trial number: UMINCTR000014453.


2016 ◽  
Vol 04 (11) ◽  
pp. E1203-E1210 ◽  
Author(s):  
Takashi Nonaka ◽  
Masahiko Inamori ◽  
Yasushi Honda ◽  
Kenji Kanoshima ◽  
Yumi Inoh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document